Use of a Autologous MiniTC MFAT Injection to Improve Knee Pain and Function Among Patients with Osteoarthritis

Principal Investigator:

Dr. Imran James Siddiqui

MD, Thomas Jefferson University

Dr. Imran James Siddiqui is board certified in both physical medicine and rehabilitation and musculoskeletal ultrasound. He is trained in cutting edge techniques in the diagnosis and treatment of joint, muscle and nerve conditions. In his practice, Dr. Siddiqui utilizes a patient-centered, holistic approach to healing with the objective of reducing pain, improving function, restoring health and preventing further injury.

Study Abstract:

This Circle is intended to evaluate the safety and efficacy of a single injection of autologous MiniTC MFAT for treatment of knee osteoarthritis.  Application of the MiniTC technology can aid in the production of a clinically relevant cell enriched autologous microfat grafts for use in the healing of degenerative joint diseases.  Over an 2-year period, this Circle captures patient-reported data related to knee pain, function, and stiffness prior to and following a one-time treatment of MiniTC MFAT.

Study Type:

Interventional

Circle Benefits:
  • Longitudinal, real-world safety and efficacy assessment of MFAT.
  • Collaboration with nationally recognized musculoskeletal physicians.
  • Clinically significant registry datasets supporting standards of care for a variety of lower extremity pathologies.
Real-World Data Surveys:
  • Visual Analogue Scale (VAS)
  • Western Ontario and McMaster Universities Arthritis Index (WOMAC)
Circle Type:

Private Circle

Interested in learning more about this Circle?
Additional Resources:

Use of a Autologous MiniTC MFAT Injection to Improve Knee Pain and Function Among Patients with Osteoarthritis

Circle Objective Abstract:

This Circle is intended to evaluate the safety and efficacy of a single injection of autologous MiniTC MFAT for treatment of knee osteoarthritis.  Application of the MiniTC technology can aid in the production of a clinically relevant cell enriched autologous microfat grafts for use in the healing of degenerative joint diseases.  Over an 2-year period, this Circle captures patient-reported data related to knee pain, function, and stiffness prior to and following a one-time treatment of MiniTC MFAT.

Real-World Data Surveys:

VAS, WOMAC

Intervention:

Circle Benefits:
  • Longitudinal, real-world safety and efficacy assessment of MFAT.
  • Collaboration with nationally recognized musculoskeletal physicians.
  • Clinically significant registry datasets supporting standards of care for a variety of lower extremity pathologies.

Streamlined patient enrollment, real-world data capturing, heightened recognition, prominence and collaboration

Circle Type:

Private Circle

Supporting Materials
Interested in learning more about this Circle?

CIRCLE LIBRARY

CIRCLE NAME

Total Knee Arthroplasty Outcome-Based Performance Measure

SURVEYS

OUTCOMES SURVEYS

VAS
KOOS Jr.
VR-12 (compliant with CMS/IQR Requirements)

CLINICAL SURVEYS

As specified by Provider

THIS CIRCLE IS FOR:

Provider Receiving CMS Reimbursement For TKAs

CMS will soon penalize providers performing total knee replacements which do not collect specified outcomes data from at least 50% of qualifying patients.

Other Providers Performing TKAs

Private insurance companies and other payers within and outside the U.S. will follow the CMS lead in requiring high patient compliance in reporting long-term TKA outcomes.

WHY CIRCLES

Patented technology
HIPAA, GDPR, GCP and Part 11 compliant
Multilingual
Scalable
Easily export to, integrate with, existing systems
Robust reporting functions
Illustrative Materials
Minimal administrative and clinical burden
Accommodates surgical variations
All data accessible 24/7 from any device
Allows extensive customization
Inherent collaboration among peers
Improves clinical decision-making
Adjustable outcomes alerts
Regular reports on key metrics
Automatic patient consent capture
Illustrative Materials
Sustained onboarding and follow-up processes
Communication of condition and protocol education materials *
Regular progress reports *
Cohort comparisons *
Newsletters, other patient communications *
*  Provider defined
Illustrative Materials
Clear ownership of validated anonymized datasets
Copyrightable
Right to publish
Right to monetize
Illustrative Materials
Not a point solution, but a strategic initiative
Easily extensible and scalable
Accommodates Health Equity initiatives
Accommodates CMS Hospital Value Program and other Value-Based Care initiatives
Clinical Grade
Patented technology
HIPAA, GDPR, GCP and Part 11 compliant
Multilingual
Scalable
Robust reporting functions
Easily export to, integrate with, existing systems
Interested in this Circle?

If you have any questions, please contact us.

ADDITIONAL RESOURCES